SCHEMBL25327912

SCHEMBL25327912

COc1ccccc1S(=O)(=O)N1CC2(CN(C(=O)N3CC4(CC(c5nnc(C6CC6)[nH]5)C4)C3)C2)C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.40
▸ HCRTR1 O43613 3/20 0.38
▸ HCRTR2 O43614 3/20 0.38
▸ CHRM4 P08173 3/20 0.38
▸ PKM P14618 1/20 0.37
▸ KEAP1 Q14145 1/20 0.35
▸ NFE2L2 Q16236 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ CLK1 P49759 1/20 0.34
▸ CHRM2 P08172 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CCNT1 O60563 1/20 0.33
▸ CDK9 P50750 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322792 0.88 AKR1C3 (0.42) AKR1C3HCRTR1HCRTR2CHRM1
SCHEMBL25325494 0.83 KMT2A (0.43) AKR1C3CHRM4ALDH1A1KMT2A
SCHEMBL25326196 0.80 AKR1C3 (0.39) AKR1C3PKMALDH1A1KMT2AMAPT
SCHEMBL27148822 0.79 MGLL (0.47) AKR1C3HCRTR1HCRTR2CHRM4PKM
SCHEMBL25324751 0.79 EPHX2 (0.41) AKR1C3KMT2A
SCHEMBL25323578 0.77 EPHX2 (0.42) HCRTR1HCRTR2PKMKMT2A
SCHEMBL25326089 0.76 NR3C1 (0.34) —
SCHEMBL30700660 0.75 AKR1C3 (0.40) AKR1C3HCRTR1HCRTR2CHRM4PKM
SCHEMBL25325171 0.75 AKR1C3 (0.38) AKR1C3ALDH1A1TSHRKMT2AHPGD
SCHEMBL25324457 0.75 GAA (0.39) AKR1C3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US claimed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP claimed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 AKR1C3 257/4885HCRTR1 41/4885HCRTR2 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback